Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW3011 in Patients With Polycythemia Vera
NCT06752746Phase 1Recruiting
- Sponsor
- Mabwell
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 9MW3011 in polycythemia vera (PV) (3 arms), sponsored by Mabwell. Primary endpoints: Adverse Event, Vital sign and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
9MW3011
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06752746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752746.